EARS2 (Glutamyl-tRNA Synthetase 2, Mitochondrial) is an essential mitochondrial aminoacyl-tRNA synthetase (mtARS) that catalyzes the charging of glutamate to its cognate mitochondrial tRNA. This enzymatic function is critical for mitochondrial protein synthesis, as mtARS enzymes are required for translating the 13 proteins encoded by the mitochondrial genome. Mutations in EARS2 cause a spectrum of mitochondrial disorders, most notably Leukoencephalopathy with thalamus and Brainstem Involvement (LBSL), and have been implicated in broader neurodegenerative processes. This comprehensive analysis examines EARS2 structure, function, disease associations, and its relationship to common neurodegenerative diseases including Alzheimer's and Parkinson's.
Gene Symbol: EARS2
Full Name: Glutamyl-tRNA Synthetase 2, Mitochondrial
Chromosomal Location: 16p12.2
NCBI Gene ID: 124454
OMIM: 614949
Ensembl ID: ENSG00000120784
UniProt ID: Q5J7C6
Gene Family: Mitochondrial aminoacyl-tRNA synthetases
Associated Diseases: LBSL, Leigh syndrome, mitochondrial encephalopathy, Perrault syndrome
¶ Structure and Catalytic Mechanism
¶ Protein Domain Organization
EARS2 is a Class I aminoacyl-tRNA synthetase with characteristic domain architecture:
¶ N-terminal Domain
The N-terminal domain (~200 amino acids) contains:
- Mitochondrial targeting sequence (MTS): A cleavable presequence that directs import into mitochondria
- Additional targeting elements for mitochondrial matrix localization
- Interaction domains for protein complex formation
¶ Catalytic Domain
The central catalytic domain contains:
- Aminoacylation domain: The active site that catalyzes glutamate activation and tRNA charging
- ATP-binding pocket: Conserved KMSKS loop that binds ATP
- ** acceptor stem binding region**: Recognizes the 3' end of tRNA
¶ C-terminal Domain
The C-terminal region includes:
- Helical domain: Mediates protein-protein interactions
- Dimerization interface: EARS2 functions as a dimer
- tRNA recognition elements: Additional binding surfaces for tRNA specificity
EARS2 catalyzes aminoacylation through a two-step process:
- Amino acid activation: Glutamate + ATP → Glutamyl-AMP + PPi
- tRNA charging: Glutamyl-AMP + tRNA^Glu → Glutamyl-tRNA^Glu + AMP
This reaction requires:
- Correct amino acid recognition
- ATP binding and hydrolysis
- Specific tRNA^Glu recognition
- Proper proofreading to prevent mischarging
EARS2 shares structural features with other Class I synthetases:
- Rossmann fold: Central β-sheet with α-helices in catalytic domain
- HIGH motif: Sequence signature in active site
- KMSKS loop: Flexible loop that closes over ATP during catalysis
- Connective polypeptide: Links domains for conformational changes
EARS2 is essential for mitochondrial protein synthesis:
- EARS2 specifically charges mitochondrial tRNA^Glu
- This tRNA decodes GAA/GAG codons
- Required for translation of 13 mitochondrial-encoded proteins:
- Complex I subunits: ND1, ND2, ND3, ND4, ND4L, ND5, ND6
- Complex III subunits: CYTB
- Complex IV subunits: COX1, COX2, COX3
- Complex V subunits: ATP6, ATP8
EARS2 participates in mitochondrial translation quality control:
- Accurate aminoacylation ensures proper protein synthesis
- Prevents incorporation of incorrect amino acids
- Connected to mitochondrial ribosome quality control
- Dysfunction leads to translational errors
EARS2 is particularly important for Complex I (NADH:ubiquinone oxidoreductase):
- Seven Complex I subunits are encoded by mitochondrial DNA
- Requires EARS2 for translation of these subunits
- Complex I deficiency is a common finding in EARS2 mutations
- Complex I defects lead to energy deficiency
EARS2 connects mitochondrial function to cellular metabolism:
- ATP production through oxidative phosphorylation
- Reactive oxygen species (ROS) management
- Metabolic signaling through mitochondrial function
- Integration with cellular stress responses
EARS2 is expressed ubiquitously with highest levels in:
- Brain: Cerebral cortex, cerebellum, brainstem, thalamus
- Heart: High expression in cardiac muscle
- Skeletal muscle: Essential for muscle function
- Liver: High metabolic activity
- Kidney: Significant expression
EARS2 is localized to:
- Mitochondrial matrix: Primary location
- Mitochondrial nucleoid: Associated with mtDNA
- Ribonucleoprotein complexes: Connected to mitochondrial ribosomes
EARS2 expression varies during development:
- Embryonic: Essential for development
- Postnatal: Maintained at high levels
- Adult: Tissue-specific expression patterns
- Aging: Altered expression in some contexts
¶ Leukoencephalopathy with Thalamus and Brainstem Involvement (LBSL)
LBSL is the primary disease associated with EARS2 mutations:
- Progressive leukoencephalopathy
- Predominant involvement of thalamus and brainstem
- Motor impairment (spasticity, ataxia)
- Cognitive decline
- Variable onset (infancy to adulthood)
- White matter abnormalities
- Thalamic involvement
- Brainstem lesions
- Characteristic MRI patterns
- Autosomal recessive inheritance
- Biallelic EARS2 mutations
- Variable severity based on mutation type
- Founder mutations in certain populations
EARS2 mutations can cause Leigh syndrome:
- Subacute necrotizing encephalomyelopathy
- Developmental regression
- Movement disorders
- Respiratory failure
- Usually infantile onset
- Bilateral basal ganglia lesions
- Brainstem involvement
- Necrotic changes
- Energy deficiency
EARS2 mutations cause multiple complex deficiencies:
- Complex I deficiency most common
- Combined deficiencies in severe cases
- Variable tissue involvement
- Progressive course
EARS2 is associated with Perrault syndrome:
- Sensorineural hearing loss
- Ovarian dysfunction (in females)
- Variable neurological features
- Mitochondrial dysfunction
Mitochondrial dysfunction is a hallmark of Alzheimer's disease, and EARS2 may play a role:
- Reduced mitochondrial translation in AD brain
- Altered expression of mtARS enzymes
- Correlation with Aβ and tau pathology
- Energy deficiency in neurons
- Complex I deficiency in AD
- EARS2 contributes to Complex I subunit synthesis
- May be affected by Aβ toxicity
- Therapeutic implications
- Glucose hypometabolism in AD brain
- Mitochondrial dysfunction contributes
- EARS2 function relates to energy production
- Connection to neuronal survival
EARS2 has several connections to Parkinson's disease:
- Primary hallmark of PD
- Complex I deficiency in substantia nigra
- EARS2 important for Complex I
- Connection to PINK1/PARKIN pathway
- Mitochondrial function affects α-syn aggregation
- EARS2 may influence protein clearance
- Autophagy-lysosome pathway involvement
- Therapeutic targets
- Dopaminergic neurons are energetically demanding
- Mitochondrial dysfunction leads to vulnerability
- EARS2 supports energy production
- Neuroprotection strategies
EARS2 and mitochondrial translation in ALS:
- Mitochondrial dysfunction in motor neurons
- Altered mitochondrial translation
- Energy failure in disease
- Therapeutic targeting
EARS2 interacts with:
| Partner |
Interaction Type |
Function |
| Mitochondrial Ribosome |
Binding |
Protein synthesis |
| tRNA^Glu |
Substrate |
Aminoacylation |
| Other mtARS |
Complex |
Translation machinery |
| Mitochondrial DNA |
Proximity |
Translation coupling |
| Complex I subunits |
Product |
Energy production |
EARS2 connects to several pathways:
- Mitochondrial protein synthesis: Central function
- OXPHOS pathway: Energy production
- Mitochondrial quality control: Connected to degradation
- Cellular stress response: Energy deficiency signaling
- Apoptosis pathway: Connected to cell death
Targeting EARS2 for therapy:
- Adeno-associated virus (AAV) vectors
- Mitochondrial targeting
- Long-term expression
- Current research stage
- siRNA for mutation silencing
- mRNA delivery for protein replacement
- Antisense oligonucleotides
- Splice-modulating approaches
Drug development strategies:
- CoQ10 and analogs
- L-carnitine
- B-vitamins
- Metabolic modulators
- Mitochondrial protein synthesis inhibitors (caution)
- Translation enhancers
- Quality control modulators
¶ Challenges and Opportunities
Key considerations:
- Mitochondrial gene delivery
- Tissue specificity
- Crossing the blood-brain barrier
- Combination approaches
Opportunities:
- Disease modification potential
- Personalized medicine
- Biomarker development
- Combination therapy
¶ Animal Models and Experimental Evidence
- EARS2 knockout is embryonic lethal
- Tissue-specific knockouts show deficiency
- Conditional models available
- Rescue experiments
- LBSL patient-derived cells
- Leigh syndrome models
- Transgenic approaches
- Phenotypic characterization
- Patient fibroblasts
- Neuronal differentiation
- Mitochondrial function assays
- Translation analysis